読み込み中
NASDAQHealthcareBiotechnology
最新データ
$1.12
−$0.03 · -2.61%
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.
前日終値
$1.12
−$0.03 · -2.61%
日中の時刻はETです。市場データは遅延する場合があります。
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.
日中レンジ
現在 $1.12
52週レンジ
現在 $1.12
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
28
割高
センチメント
53
まちまち
リスク
66
高リスク
モメンタム
34
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.
日中レンジ
現在 $1.12
52週レンジ
現在 $1.12
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 243.56万 USD | 223.53万 USD | 157.43万 USD | 83.32万 USD | 12.65万 USD |
| 販売・一般管理 | 810.33万 USD | 963.63万 USD | 60.02万 USD | 2.09万 USD | 1.16万 USD |
| 営業費用 | 1053.88万 USD | 1224.22万 USD | 394.2万 USD | 85.41万 USD | 13.81万 USD |
| 受取利息 | 12.56万 USD | 4.8万 USD | — | — | — |
| 支払利息 | — | −433.85万 USD | 164.3万 USD | — | — |
| 減価償却費と償却費 | — | 433.85万 USD | — | 85.41万 USD | 13.81万 USD |
| 営業利益 | −1053.88万 USD | −1224.22万 USD | −394.2万 USD | −85.41万 USD | −13.81万 USD |
| 純利益 | −1041.32万 USD | −1653.27万 USD | −1307.19万 USD | −85.41万 USD | −13.81万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$4.00
上昇余地（257.14%）この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
